Glass Wall Syndicate
VC Fund
Glass Wall Syndicate is a VC fund focused on Biotechnology and Food and Beverage. Glass Wall Syndicate invests in companies and products that will make a difference in the lives of animals, people, and the planet. It helps grow companies in this space by providing them with capital, resources, mentorship, and other forms of support.The firm is consists of a group of venture capitalists, foundations, trusts, non-profits, andindividual investors who share a similar investment thesis and want to accelerate mainstream adoption of products and services that will make a difference in the lives of animals, people and that are better for the planet.
- Total investments:
- 8
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Glass Wall Syndicate invests in
Stages Glass Wall Syndicate invests in
Countries Glass Wall Syndicate invests in
Round sizes
Round size
- Seed
- $845k–$5.7M
- Pre-Seed
- $1.6M–$2M
Investment Focus
Industry
- Biotechnology 5 (63%)
- Food and Beverage 4 (50%)
- Health Care 2 (25%)
- Food Processing 2 (25%)
- Beauty 1 (13%)
Stage
- Seed 4 (50%)
- Pre-Seed 2 (25%)
- Series C 1 (13%)
- Funding Round 1 (13%)
Country
- United States 5 (63%)
- India 1 (13%)
- Sweden 1 (13%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Uncaged Innovations develops next-generation materials to recreate bovine and exotic leather through advancements in materials chemistry and digital manufacturing, providing businesses from luxury fashion to automotives with an alternative to animal skin and sustainable and ethical services. | $2M / Pre-Seed / Jun 02, 2023 | ||
| MeliBio is a technology-based company focusing on plant biology, precision fermentation, and food science that replaces honeybees with microorganisms as a medium for honey production. The company was founded in 2020 by Aaron M. Schaller, PhD and Darko Mandich and is headquartered in Oakland, California, United States. TIME named MeliBio'sapproach in making honey without bees as Best Inventions 2021. In 2023, MeliBio launched consumer-facing brand Mellody. | $5.7M / Seed / Mar 17, 2022 | ||
| Cultured Decadence is a cellular aquaculture startup creating novel methods to make crustacean products using cell culture and tissue engineering techniques. The company was founded in 2020 and based in Madison, Wisconsin. | $1.6M / Pre-Seed / Apr 09, 2021 | ||
| Evo Foods is a food processing company that manufactures and produces a delicious and fluffy plant-based egg alternative. Its first product is a 100% plant-based liquid egg made from lentil protein that contains no cholesterol or antibiotics. The company is using cutting-edge science and technology to develop the next generation of plant-basedalternatives to animal products. Its plant-based liquid egg is created with the startup's proprietary patent-pending technology and indigenous Indian ingredients such as moong beans and peas. | $845K / Seed / Apr 04, 2021 | ||
| Mycorena is a fungi-based, next-generation vegan protein and food manufacturing solution to plants, using significantly less resources. Mycorena was established in 2017 and is headquartered in Gothenburg, Sweden. | $1.3M / May 19, 2020 | ||
| Mycorena is a fungi-based, next-generation vegan protein and food manufacturing solution to plants, using significantly less resources. Mycorena was established in 2017 and is headquartered in Gothenburg, Sweden. | $1.3M / Seed / May 19, 2020 | ||
| Grounded Foods Co. makes plant-based cheeses from a proprietary fermentation process, using imperfect vegetables and hemp seed. This results in products that are extremely similar in flavor and texture to dairy cheese, with high nutritional value and environmental resilience.Founded by Australian entrepreneurs Veronica Fil (behavioral economist)and Shaun Quade (international award-winning chef). The duo is regularly misquoted in media and tech platforms such as Crunchbase, but figure “f#%k it, all exposure is good if it gets people eating dairy-free cheese”. | $1.7M / Seed / Mar 15, 2020 | ||
| Emulate is a privately held company that creates advanced in vitro models for understanding how diseases, medicines, chemicals, and foods affect human health. | $36M / Series C / Jun 18, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Glass Wall Syndicate invest in?
Glass Wall Syndicate invests primarily in Biotechnology, Food and Beverage and Health Care startups, most often at Seed and Pre-Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Glass Wall Syndicate invest in?
Glass Wall Syndicate typically joins rounds of $845k–$5.7M at Seed and $1.6M–$2M at Pre-Seed. These are whole funding-round sizes, not Glass Wall Syndicate's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Glass Wall Syndicate took part in.
When did Glass Wall Syndicate last invest?
The most recent investment recorded for Glass Wall Syndicate closed in Jun 2023. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
